Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial.
- Published In:
- Molecular autism, 3(1), 16 (2012)
- Authors:
- Anagnostou, Evdokia, Soorya, Latha, Chaplin, William, Bartz, Jennifer, Halpern, Danielle, Wasserman, Stacey, Wang, A Ting, Pepa, Lauren, Tanel, Nadia, Kushki, Azadeh, Hollander, Eric
- Database ID:
- RPEP-01896
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01896APA
Anagnostou, Evdokia; Soorya, Latha; Chaplin, William; Bartz, Jennifer; Halpern, Danielle; Wasserman, Stacey; Wang, A Ting; Pepa, Lauren; Tanel, Nadia; Kushki, Azadeh; Hollander, Eric. (2012). Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial.. Molecular autism, 3(1), 16. https://doi.org/10.1186/2040-2392-3-16
MLA
Anagnostou, Evdokia, et al. "Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial.." Molecular autism, 2012. https://doi.org/10.1186/2040-2392-3-16
RethinkPeptides
RethinkPeptides Research Database. "Intranasal oxytocin versus placebo in the treatment of adult..." RPEP-01896. Retrieved from https://rethinkpeptides.com/research/anagnostou-2012-intranasal-oxytocin-versus-placebo
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.